À cells compared with their normal counterparts was assessed by quantitating the effect of specific ABCB1 modulators (verapamil and PSC-833) on mitoxantrone retention [defined as efflux index (EI), intracellular mitoxantrone fluorescence intensity in the presence/absence of inhibitor]. Results: ABCB1 was the major drug transporter in CD34 + CD38
etic CD34
+ CD38 À progenitor cells. Modulation of the multidrug ATP-binding cassette transporter ABCB1 has not resulted in improved outcome in AML, raising the question whether leukemic CD34 + CD38
À cells are targeted by this strategy. Experimental Design: ABCB1-mediated transport in leukemic CD34 + CD38
À cells compared with their normal counterparts was assessed by quantitating the effect of specific ABCB1 modulators (verapamil and PSC-833) on mitoxantrone retention [defined as efflux index (EI), intracellular mitoxantrone fluorescence intensity in the presence/absence of inhibitor]. Results: ABCB1 was the major drug transporter in CD34 + CD38
À cells in normal bone marrow (n = 16), as shown by the abrogation of mitoxantrone extrusion by ABCB1 modulators (EI, 1.99 F 0.08). Surprisingly, ABCB1-mediated drug extrusion was invariably reduced in CD34 + CD38 À cells in AML (n = 15; EI, 1.21 F 0.05; P < 0.001), which resulted in increased intracellular mitoxantrone retention in these cells (mitoxantrone fluorescence intensity, 4.54 F 0.46 versus 3.08 F 0.23; P = 0.004). Active drug extrusion from these cells occurred in the presence of ABCB1modulators in the majority of samples, pointing in the direction of redundant drug extrusion mechanisms. Residual normal CD34 + CD38 À cells could be identified by their conserved ABCB1-mediated extrusion capacity. Conclusion: ABCB1-mediated drug extrusion is reduced in leukemic CD34 +
CD38
À progenitor cells compared with their residual normal counterparts. Redundant drug transport mechanisms confer mitoxantrone transport from leukemic progenitors. These data argue that ABCB1 modulation is not an effective strategy to circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal progenitors in AML.
Acute myelogenous leukemia (AML) is considered a disease originating from CD34 + CD38 À hematopoietic stem cells (1) .
This has been conclusively shown in studies using the nonobese diabetic-severe combined immunodeficient mouse model showing that cells with leukemic engraftment and selfrenewal potential in AML are found in the CD34 + CD38 À subpopulation (2) . This CD34 + CD38 À phenotype of leukemiainitiating cells was observed regardless of the lineage markers expressed by the leukemic blasts, percentage of cells expressing the CD34 surface antigen, or the French-American-British subtype. These studies stress that leukemia-initiating transformation and progression-associated genetic events occur at the level of these primitive CD34 + CD38 À cells. Consequently, incomplete chemotherapeutic eradication of these cells may ultimately result in disease relapse. Therefore, elucidation of the mechanisms conferring resistance against chemotherapy to these cells is of crucial importance (3). The ABCB1-encoded P-glycoprotein is a highly conserved membrane-bound ATP-binding cassette (ABC) transporter, which extrudes a wide variety of structurally unrelated chemotherapeutic compounds across the cell membrane (4), conferring the multidrug resistance phenotype in cancer cells. ABCB1 is highly expressed in normal hematopoietic CD34 + CD38
À stem cells (5, 6) .
The observation that it is frequently expressed in AML and that expression is associated with adverse treatment outcome (7) has led to the introduction of ABCB1 modulators to enhance chemotoxicity of various chemotherapeutic agents in clinical trials. Phase III clinical trials using PSC-833 (valspodar), the most potent and specific inhibitor of ABCB1 function today, however, failed to reach their intended end points of improved complete remission and survival and have been complicated by increased toxicity (8 -12) . In contrast, a clinical trial using cyclosporin A, which is a broad-spectrum ABC transporter inhibitor, showed clinical benefit (13) . The reasons for the lack of benefit of ABCB1 modulation in AML remain to be elucidated. In interpreting these negative results, it is important to know whether the leukemia-initiating CD34 +
À hematopoietic subpopulation is targeted by ABCB1 modulation and whether additional transporters confer drug extrusion from these cells, which may explain the beneficial effect of broad-spectrum inhibition. The vast amount of studies on ABCB1 expression and function in AML has been done on general blast populations. The goal of the current study was to investigate ABCB1 expression and function in leukemic CD34 + CD38 À cells and the effect of ABCB1 modulators on drug retention in these cells compared with their normal counterparts.
Materials and Methods
Bone marrow samples. Bone marrow was obtained after informed consent from healthy bone marrow donors and patients with AML at diagnosis. Mononuclear cells were isolated by Ficoll (1.077 g/mL density centrifugation; Pharmacy Biotech, Uppsala, Sweden). Isolation, cryopreservation, and thawing procedures of cells have been described previously (14) and were identical for normal and leukemic bone marrow samples. CD34
À cells were defined flow cytometrically as described previously (15) and are shown in Fig. 1A .
Flow cytometric assessment of ABCB1 expression. ABCB1 expression was analyzed using the ABCB1-specific antibody MRK16, recognizing an external epitope of the protein in three-color flow cytometric assays as described previously (7) . ABCB1 protein expression was quantitated as the median fluorescence channel shift (MRK16/IgG2a isotype control) in CD34 Flow cytometric assessment of ABCB1-mediated mitoxantrone transport. Cells were stained with CD34-FITC and CD38-PE membrane markers, washed in HBSS 1% FCS, and preincubated with or without verapamil (20 Ag/mL; Knoll AG, Ludwigshafen, Germany; ref. 16) 19) , although inhibition of ABCG2 by verapamil has been described at higher concentrations (20) . Mitoxantrone (Novantrone;10 Amol/L; Lederle, Etten-Leur, the Netherlands) was added, and cells were incubated for 2 hours at 37jC, 5% CO 2 , with or without verapamil or PSC-833. Subsequently, cells were allowed an additional 1-hour efflux in drug-free medium with or without inhibitor. The combined uptake and efflux with or without inhibitor assay was chosen because it has higher sensitivity for ABC transporter function compared with assays using only uptake with or without inhibitor (15) .
Cellular mitoxantrone fluorescence was measured at a single time point after the additional hour of efflux in drug-free medium on a flow cytometer (Coulter Elite, Beckman Coulter, Fullerton, CA) equipped with an argon laser. Fluorescence was assessed at an excitation wavelength of 635 nm through a 670-nm bandpass filter in a three-color protocol with CD34-FITC and CD38-PE. . Cells were allowed to adhere for 10 minutes in a perfusion chamber constructed to enable cell environment manipulation (incubation and washing steps) within the microscope environment. The microscope was placed in an incubator to allow all procedures to run at 37jC, which is essential for physiologic efflux studies.
After immobilization, cells were incubated with rhodamine 123 dissolved in Iscove's modified Dulbecco's medium containing 0.5% (v/v) heat-inactivated FCS (Hyclone, Logan, UT) with or without efflux modulator during 30 minutes. Cells were washed with washing buffer at 37jC, again in the presence or absence of efflux modulators, and allowed to efflux the dye for an additional 15 minutes. Fluorescence images were acquired after 15 minutes of efflux. Cells were excited with a mercury arc lamp using bandpass filter of 440 to 490 nm for rhodamine 123 or bandpass filter of 510 to 560 nm for propidium iodide. Emission was measured with bandpass filter of 515 to 565 nm and longpass filter of 610 nm. Cell viability typically exceeded 90% of cells. Dead cells were excluded from analysis.
Fluorescence intensity analysis of individual cells was done on TCLImage 4.6 software package (TNO, Delft, the Netherlands). At least 30 cells were evaluated per sample. Fluorescence intensity of the overall cell population is expressed as MFI and depicted in arbitrary fluorescence units. ABCB1-mediated efflux was quantitated as the ratio of mean fluorescence intensity in the presence or absence of verapamil and depicted as ''EI. ' Normalized gene expression to the internal standard glyceraldehyde-3-phosphate dehydrogenase is given by the following equation: To/ Ro(Xn) = K (1 + E) (CT,r À CT,t) , where To is the initial number of target gene copies, Ro is the initial number of standard gene copies, E is the efficiency of amplification, CT,t is the threshold cycle of target gene, CT,r is the threshold cycle of standard gene, and K is constant.
Statistical analysis. Differences in ABCB1 protein expression (D of MRK16/isotype control) and function (EI) between different normal and leukemic cell populations were calculated using the Student's t test with a level of significance of P < 0.05. Fig. 3A ). Serial measurements of mitoxantrone fluorescence in CD34 + CD38 À cells both after 2-hour exposure with mitoxantrone and after an additional hour of efflux in drug-free medium done in a subpanel of samples (n = 7) showed complete abrogation of mitoxantrone extrusion by ABCB1 modulation (Fig. 4A) . Verapamil is regarded ABCB1 specific, although inhibition of ABCG2 (BCRP) has been observed at concentrations considerably higher than used in our experiments. To definitely confirm that the drug efflux from normal CD34 + CD38
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À cells was indeed ABCB1 mediated, additional experiments were done. First, similar results were found when the ABCB1-specific inhibitor PSC-833 was used in a subgroup of samples (n = 4; mean EI F SE, 2.03 F 0.12 and 1.38 F 0.09 for CD34 + CD38
À and CD34 + CD38 + cells, respectively; Fig. 1B) , showing that the observed efflux is ABCB1 rather than BCRP mediated because PSC833 is not an inhibitor of BCRP. This was further confirmed using rhodamine 123 as a substrate, which is not a substrate for BCRP (23) , in an independent assay in single CD34 + CD38
À cells sorted on an adhesive biolayer (Fig. 1C) Fig. 3B ). Of interest, analysis of mitoxantrone efflux mediated by the ABC transporters ABCG2 (BCRP), done in a series of normal and leukemic bone marrow samples, including those described in this article, using the ABCG2-specific fumitremorgin C analogue KO143 as inhibitor, showed no difference between normal and leukemic CD34 + CD38 À cells (15) , further
showing that the observed decrease in mitoxantrone efflux is indeed due to deficient ABCB1 rather than ABCG2 activity. Serial measurements both after 2 hours of drug exposure and after an additional hour in drug-free medium in a subpanel of AML samples (n = 10; Fig. 4B ) showed significant extrusion of mitoxantrone in the presence of verapamil in the majority of patients, pointing in the direction of redundant drug extrusion mechanisms.
These redundant drug transport mechanisms, however, did not compensate for the reduced ABCB1-mediated transport from leukemic CD34 
Discussion
In this report, we show that ABCB1-mediated drug transport is reduced in leukemic CD34 + CD38 À progenitor cells compared with their normal counterparts in AML. This finding was initially unanticipated because AML is generally considered to be an ABCB1-overexpressing malignancy with conserved physiologic function (25) . This assumption, however, is based on the observation that ABCB1 is preferentially expressed in CD34 + blasts in AML (26) similar to preferential expression of ABCB1 in these cells in normal bone marrow (27) , thus reflecting similar patterns of expression rather than direct comparison of ABCB1 expression and function of normal and malignant cell subpopulations. Expression data in our study confirm the preferential expression of ABCB1 in CD34 + cells in AML (26) (28) earlier, pointing in the direction of the presence of nonfunctional forms of the ABCB1 protein, but the current report, aimed at directly comparing ABCB1 function between normal and leukemic primitive progenitor cells, shows that impaired ABCB1 function is a biological commonality rather than an occasional finding in AML. The molecular determinants behind impaired ABCB1-mediated transport in hematopoietic cells in AML remain to be elucidated and may comprise both downstream event of oncoproteins central in leukemogenesis, such as AML1-ETO (29) and TEL-AML1 (30) , and factors governed by the cellular environment, such as disruption of cellular ATP metabolism, membrane integrity, or cell cycle regulation (31) . cells but that this redundant action does not completely compensate for the reduced ABCB1 function in these cells.
The combined data suggest that the prognostic value of ABCB1, one of the main rationales for ABCB1 targeting in AML, may be pleiotropoic, identifying leukemias with a primitive CD34 + (CD38 À ) character and innate drug resistance due to differential expression of many, promiscuous ABC transporters and possibly other mechanisms protecting primitive progenitor cells. Modulation of additional transporters is therefore likely to be required to abrogate drug extrusion and to enhance druginduced eradication of leukemic stem cells in AML. These laboratory findings provide an alternative explanation for the poor results of ABCB1 modulation by the highly potent ABCB1 inhibitor PSC-833 and other inhibitors on long-term disease outcome in clinical trials (8 -10) . The report of improved clinical outcome in a trial using cyclosporin as an ABCB1 inhibitor in AML (13) may reflect these findings because cyclosporin is a more promiscuous ABC transporter inhibitor with effects on ABCB1 and other ABC transporters (33) .
Additionally, the current study shows that residual normal CD34 + CD38
À cells are likely to harbor within the ABCB1 efflux ++ subpopulation. This seems congruent with the report (34) 
